首頁 > 市場調查報告書 > 製藥

癌症呼吸器

非小細胞肺癌市場規模、佔有率和成長分析：按治療方法、癌症類型、生物標記、分銷管道和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2035706

非小細胞肺癌市場規模、佔有率和成長分析：按治療方法、癌症類型、生物標記、分銷管道和地區分類－2026-2033年產業預測

Non-Small Cell Lung Cancer Market Size, Share, and Growth Analysis, By Therapy Type, By Cancer Type, By Biomarker Type, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月05日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球非小細胞肺癌市場價值為 306.8 億美元，預計到 2025 年將成長至 349.4 億美元，到 2033 年將成長至 989.8 億美元，在預測期（2026-2033 年）內複合年成長率為 13.9%。

非小細胞肺癌 (NSCLC) 市場正經歷顯著成長，這主要得益於免疫查核點抑制劑 (ICI) 一線治療方案的引入。 NSCLC 佔全球肺癌病例的 80% 至 85%，主要市場參與者正致力於開發創新治療方法並提高現有療法的療效。 NSCLC 是全球最常見且致死率最高的癌症之一，這一事實進一步推動了市場擴張。 NSCLC 診斷率的上升，以及已開發市場和新興市場公眾意識的提高，是推動市場成長的關鍵因素。此外，NSCLC 療法被納入主要公司的研發管線，以及研發投入的增加，也正在推動全球市場成長。

全球非小細胞肺癌市場成長要素

多種因素正在推動全球非小細胞肺癌（NSCLC）市場的擴張。肺癌發生率不斷上升，主要原因是吸煙、石棉、鎘和氡等環境污染物以及愛滋病毒感染率的增加。此外，人口的持續成長也顯著增加了罹患肺癌的風險族群。這些相互關聯的因素正在推動NSCLC市場對創新治療方法和治療方法的需求，凸顯了醫療保健解決方案亟需改進以應對這一嚴重的公共衛生問題的緊迫性。

全球非小細胞肺癌市場的限制因素

全球非小細胞肺癌市場面臨的主要挑戰之一是治療費用高。儘管化療、手術、標靶治療、放射線治療和免疫療法等多種治療方案有效，但都帶來了沉重的經濟負擔。高昂的費用可能導致患者無法獲得必要的醫療服務，並可能限制市場整體成長。因此，治療高成本是限制非小細胞肺癌市場擴張的主要因素，凸顯了開發更經濟實惠的解決方案以改善病患就醫途徑和提升市場潛力的必要性。

全球非小細胞肺癌市場趨勢

全球非小細胞肺癌 (NSCLC) 市場正經歷顯著成長，這主要得益於已開發市場和新興市場診斷率的上升以及公眾意識的增強。領先的製藥公司對研發的大量投入進一步推動了這一趨勢，加速了創新治療方法的上市。此外，將先進治療方法和個人化醫療融入治療方案，正在改善患者預後並提振市場需求。隨著相關人員攜手合作，致力於提高新治療方法的可及性，NSCLC 市場預計將強勁擴張，這反映了全球為應對這一常見癌症而做出的更廣泛努力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

F. Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca plc
Bristol-Myers Squibb Company
Merck & Co., Inc.
Pfizer Inc.
Sanofi SA
Johnson & Johnson
Eli Lilly and Company
Amgen Inc.
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc.
AbbVie Inc.
Bayer AG
BeiGene, Ltd.
Exelixis, Inc.

結論與建議

簡介目錄

Product Code: SQMIG25K2005

Global Non-Small Cell Lung Cancer Market size was valued at USD 30.68 Billion in 2024 and is poised to grow from USD 34.94 Billion in 2025 to USD 98.98 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026-2033).

The market for non-small cell lung cancer (NSCLC) is experiencing significant growth, driven primarily by the introduction of immune checkpoint inhibitors (ICIs) in first-line treatment. NSCLC accounts for 80-85% of global lung cancer cases, prompting major market players to focus on developing innovative therapies and enhancing the efficacy of existing treatments. The disease's status as one of the most common and deadly cancers worldwide further fuels market expansion. Rising rates of NSCLC diagnoses, coupled with heightened public awareness in both developed and emerging markets, are pivotal to this growth. Additionally, the inclusion of NSCLC therapies in the research pipelines of leading companies, along with increased investment in R&D initiatives, is propelling the global market forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Small Cell Lung Cancer Market Segments Analysis

Global Non-Small Cell Lung Cancer Market is segmented by Therapy Type, Cancer Type, Biomarker Type, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Others. Based on Cancer Type, the market is segmented into Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma and Others. Based on Biomarker Type, the market is segmented into EGFR Mutation, ALK Rearrangement, ROS1 Mutation, BRAF Mutation, PD-L1 Expression and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Small Cell Lung Cancer Market

Several factors are contributing to the expansion of the global non-small cell lung cancer (NSCLC) market. The prevalence of lung cancer is increasing, largely attributed to smoking habits, environmental pollutants such as asbestos, cadmium, and radon, as well as the growing incidence of HIV infections. Additionally, the continuous rise in population contributes significantly to the number of individuals at risk for developing lung cancer. These interconnected elements are creating a heightened demand for innovative treatments and therapies in the NSCLC market, emphasizing an urgent need for advancements in healthcare solutions to tackle this serious public health issue.

Restraints in the Global Non-Small Cell Lung Cancer Market

One of the significant challenges facing the global non-small cell lung cancer market is the high cost of treatments. Various therapeutic options, including chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy, although effective, come with substantial financial burdens. This elevated price point can deter patients from accessing necessary care and may limit overall market growth. Consequently, the expensive nature of these treatments poses a considerable restraint to the expansion of the non-small cell lung cancer market, highlighting the need for more affordable solutions to improve patient access and enhance market potential.

Market Trends of the Global Non-Small Cell Lung Cancer Market

The Global Non-Small Cell Lung Cancer (NSCLC) market is witnessing significant growth driven by rising diagnoses and heightened awareness across both developed and emerging economies. This trend is further supported by leading pharmaceutical companies investing heavily in research and development, which is catalyzing the introduction of innovative treatment options. Additionally, the integration of advanced therapeutic modalities and personalized medicine into treatment protocols is enhancing patient outcomes and fueling market demand. As stakeholders collaborate to improve access to novel therapies, the NSCLC market is positioned for robust expansion, reflecting a broader commitment to tackling this prevalent cancer on a global scale.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Pricing Analysis
Case Studies
Technology Analysis
Pipeline Analysis
Disease Epidemiology
Patent Analysis

Global Non-Small Cell Lung Cancer Market Size by Therapy Type & CAGR (2026-2033)

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Others

Global Non-Small Cell Lung Cancer Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Others

Global Non-Small Cell Lung Cancer Market Size by Biomarker Type & CAGR (2026-2033)

Market Overview
EGFR Mutation
ALK Rearrangement
ROS1 Mutation
BRAF Mutation
PD-L1 Expression
Others

Global Non-Small Cell Lung Cancer Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Non-Small Cell Lung Cancer Market Size & CAGR (2026-2033)

North America (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- US
- Canada
Europe (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments